MicroRNA-155 deficiency attenuates liver steatosis and fibrosis without reducing inflammation in a mouse model of steatohepatitis

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Csak, Timea ^a   Bala, Shashi ^a   Lippai, Dora ^b   Kodys, Karen ^a   Catalano, Donna ^a   Iracheta Vellve, Arvin ^a   Szabo, Gyongyi ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CASPASE 3; CCAAT ENHANCER BINDING PROTEIN BETA; COLLAGEN TYPE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MICRORNA 155; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VIMENTIN; CHOLINE; LIPOPOLYSACCHARIDE; METHIONINE; MICRORNA; MIRN155 MICRORNA, MOUSE; PROTEIN BINDING; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FATTY ACID METABOLISM; FATTY LIVER; FEMALE; GENE CONTROL; GENE EXPRESSION REGULATION; GENE FUNCTION; KUPFFER CELL; LIPID STORAGE; LIVER CELL; LIVER FIBROSIS; LIVER HISTOLOGY; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE LEVEL; TRANSCRIPTION INITIATION; UPREGULATION; WILD TYPE; ANIMAL; C57BL MOUSE; CELL NUCLEUS; COMPLICATION; DIET; DISEASE MODEL; GENETICS; INFLAMMATION; LIPID METABOLISM; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY;

MUS;

ANIMALS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL NUCLEUS; CHOLINE; DIET; DISEASE MODELS, ANIMAL; FATTY LIVER; FEMALE; GENE EXPRESSION REGULATION; INFLAMMATION; LIPID METABOLISM; LIPOPOLYSACCHARIDES; LIVER; LIVER CIRRHOSIS; METHIONINE; MICE, INBRED C57BL; MICRORNAS; PROTEIN BINDING; SMAD3 PROTEIN; TUMOR NECROSIS FACTOR-ALPHA; VIMENTIN;

EID: 84934980367     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129251     Document Type: Article

References (57)

1. Szabo G, Bala S. MicroRNAs in liver diseases. Nat Rev Gastroenterol Hepatol. 2013; 10: 542-552. doi: 10.1038/nrgastro.2013.87 PMID: 23689081
2. Cheung O, Puri P, Eicken C, Contos MJ, Mirshani F, Maher JW, et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008; 48:1810-1820. doi: 10.1002/hep.22569 PMID: 19030170
3. Estep M, Armistead D, Hossain N, Elarainy H, Goodman Z, Baranova A, et al. Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010; 32: 487-497. doi: 10.1111/j.1365-2036.2010.04366.x PMID: 20497147
4. Dolganiuc A, Petrasek J, Kodys K, Catalano D, Mandrekar P, Velayudham A, et al. MicroRNA expression profile in Lieber-DiCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol Clin Exp Res. 2009; 33: 1704-1710. doi: 10.1111/j.1530-0277.2009.01007.x PMID: 19572984
5. Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T, et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009; 50: 1152-1161. doi: 10.1002/hep.23100 PMID: 19711427
6. Csak T, Velayudham A, Hritz I, Petrasek J, Levin I, Lippai D, et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol. 2011; 300: G433-G441. doi: 10.1152/ajpgi.00163.2009 PMID: 21233280
7. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1 beta in mice. Gastroenterology 2010; 139: 323-34.e7. doi: 10.1053/j.gastro.2010.03.052 PMID: 20347818
8. Tili E, Michaille JJ, Costinean S, Corce CM. MicroRNAs, the immune system and rheumatic disease. Nat Clin Pract Rheum. 2008; 4: 534-541.
9. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol. 2007; 179, 5082-5089. PMID: 17911593
10. Bala S, Szabo G. MicroRNA Signature in Alcoholic Liver Disease. Int J Hepatol. 2012; 2012: 498232. doi: 10.1155/2012/498232 PMID: 22518321
11. Bala S, Marcos M, Kodys K, Csak T, Catalano D, Mandrekar P, et al. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor {alpha} (TNF{alpha}) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem. 2011; 286: 1436-1444. doi: 10.1074/jbc.M110.145870 PMID: 21062749
12. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA. 2007; 104: 1604-1609. PMID: 17242365
13. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in non-alcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887. doi: 10.1002/hep.22848 PMID: 19291785
14. Imajo K, Yoneda M, Kessoku T, Oqawa J, Maeda S, Sumida Y, et al. Rodent models of nonalcoholic fatty liver disease/ nonalcoholic steatohepatitis. Int J Mol Sci. 2013; 14: 21833-21857. doi: 10.3390/ijms141121833 PMID: 24192824
15. Miller AM, Gilchrist DS, Nijjar J, Araldi E, Ramirez CM, Lavery CA, et al. MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS One 2013; 8: e72324. doi: 10.1371/journal.pone.0072324 PMID: 23991091
16. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol. 2012; 590 (Pt3): 447-458.
17. Elpek GO. Cellular and molecular mechanisms in the development of liver fibrosis: An update. World J Gastroenterol. 2014; 20: 7260-7276. doi: 10.3748/wjg.v20.i23.7260 PMID: 24966597
18. Csak T, Ganz M, Pespisa J, Kodys K, Dolagniuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011; 54: 133-144. doi: 10.1002/hep.24341 PMID: 21488066
19. Kleiner DE, Brunt EM, Natta MV, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321. PMID: 15915461
20. Nath B, Levin I, Csak T, Petrasek J, Mueller C, Kodys K, et al. Hepatocyte-specific hypoxia-inducible factor-1α is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice. Hepatology 2011; 53: 1526-1537. doi: 10.1002/hep.24256 PMID: 21520168
21. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009; 49: 989-997. doi: 10.1002/hep.22711 PMID: 19115316
22. Magnusson B, Asp L, Boström P, Ruiz M, Stillemark-Billton P, Linden D, et al. Adipocyte differentiation-related protein promotes fatty acid storage in cytosolic triglycerides and inhibits secretion of very low density lipoproteins. Atheroscler Thromb Vasc Biol. 2006; 26: 1566-1571. PMID: 16627799
23. Zammit VA. Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia. Biochem J. 2013; 451: 1-12. doi: 10.1042/BJ20121689 PMID: 23489367
24. Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM. Mechanism of hepatic steatosis in mice fed a lipogenic methionine-choline deficient diet. J Lipid Res. 2008; 49: 1068-1076. doi: 10.1194/jlr.M800042-JLR200 PMID: 18227531
25. Thumser AE, Moore JB, Plant NJ. Fatty acid binding proteins: tissue-specific functions in health and disease. Curr Opin Clin Nutr Metab Care. 2014; 17: 124-129. doi: 10.1097/MCO.0000000000000031 PMID: 24500438
26. Ai D, Chen C, Han S, Ganda A, Murphy AJ, Haeusler R, et al. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J Clin Invest. 2012; 122(4): 1262-1270. doi: 10.1172/JCI61919 PMID: 22426206
27. Patel DD, Knight BL, Wiggins D, Humpreys SM, Gibbons GF. Distrubances in the normal regulation of SREBP-sensitive genes in PPAR-alpha deficient mice. J Lipid Res. 2001; 42(3): 328-337. PMID: 11254743
28. Zeng L, Tang WJ, Yin JJ, Zhou BJ. Signal transductions and nonalcoholic fatty liver: a mini-review. World J Gastroenterol. 2014; 7(7): 1624-1631.
29. FonTacer K, Rozman D. Nonalcoholic fatty liver disease: Focus on lipoprotein and lipid deregulation. J Lipids. 2011; ID:783976.
30. Dattaroy D, Pourhoseini S, Das S, Alhasson F, Seth RK, Nagarkatti M, et al. Micro RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin mediated NADPH oxidase in experiemental and human non-alcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2014 In press; 2014 Dec 11: ajpgi.00346.2014. doi: 10.1152/ajpgi.00346.2014
31. Chakraborty JB, Oakley F, Walsh MJ. Mechanisms and Biomarkers of Apoptosis in Liver Disease and Fibrosis. Int J Hepatol. 2012; 2012: 648915. doi: 10.1155/2012/648915 PMID: 22567408
32. Louafi F, Martinez-Nunez RT, Sanchez-Elsner T. MicroRNA-155 targets Smad2 and modulates the reponse of macrophages to transforming growth factor-β. J Biol Chem. 2010; 285: 41328-41336. doi: 10.1074/jbc.M110.146852 PMID: 21036908
33. Johansson J, Berg T, Kurzejamska E, Pang MF, Tabor V, Jansson M, et al. MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene 2013; 32: 5614-5624. doi: 10.1038/onc.2013.322 PMID: 23955085
34. Li J, Shan F, Xiong G, Chen X, Guan X, Wang JM, et al. Epidermal Growth Factor-induced C/EBPbeta participates in EMT by dampening miR203 in esophageal squamous cell carcinoma. J Cell Sci. 2014; 127(Pt17): 3735-3744.
35. Lekstrom-Himes J, Xathopoulos KG. Biological role of the CCAAT/Enahncer binding protein family of transcription factors. J Biol Chem. 1998; 273: 28545-28548. PMID: 9786841
36. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013; 10: 656-665. doi: 10.1038/nrgastro.2013.183 PMID: 24080776
37. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association of the Study for Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023. doi: 10.1002/hep.25762 PMID: 22488764
38. Poqribny IP, Starland-Davenport A, Tryndyak VP, Han T, Ross SA, Rusyn I, et al. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest. 2010; 90: 1437-1446. doi: 10.1038/labinvest.2010.113 PMID: 20548288
39. Adams LA, Lymp JF, Sauver J, St, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121. PMID: 16012941
40. Edvardsson U, Ljungberg A, Linden D, William-Olsson L, Peilot-Sjögren J, Ahnmark A, et al. PPARalpha activation increases triglyceride mass and adipocyte differentiation-related protein in hepatocytes. J Lipid Res. 2006; 47(2): 329-340. PMID: 16282640
41. Paland N, Gamliel-Lazarovich A, Coleman R, Fuhrman B. Urokinase-type plasminogen activator (uPA) stimulates triglyceride synthesis in Huh7 hepatoma cells via p38-dependent upregulation of DGAT2. Atherosclerosis 2014; 237(1): 200-207. doi: 10.1016/j.atherosclerosis.2014.09.003 PMID: 25244504
42. Feingold KR, Wang Y, Moser A, Shigenaga JK, Grunfeld C. LPS decreases fatty acid oxidation and nuclear hormone receptors in the kidney. J Lipid Res. 2008; 49(10): 2179-2187. doi: 10.1194/jlr.M800233-JLR200 PMID: 18574256
43. Rakhshandehroo M, Knoch B, Muller M, Kersten S. Peroxisome Proliferator-Activated Receptor Alpha Target Genes. PPAR Research 2010; ID: 612089.
44. Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007; 46(5): 1392-1403. PMID: 17929294
45. Kainuma N, Fujimoto M, Sekiya N, Tsuneyama K, Cheng C, Takano Y, et al. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol. 2006; 41(10): 971-980. PMID: 17096066
46. Day CP, James OF. Steatohepatitis" a tale of two "hit"? Gastroenterology 1998; 114: 842-845. PMID: 9547102
47. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45: 1366-1374. PMID: 17476695
48. Witek RP, Stone WC, Karaca FG, Syn WK, Pereira TA, Agboola KM, et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of steatohepatitis. Hepatology 2009; 50(5): 1421-1430. doi: 10.1002/hep.23167 PMID: 19676126
49. Yang L, Seki E. Toll like receptors in liver fibrosis: cellular crosstalk and mechanisms. Front Physiol. 2012; 3: Article 138.
50. Yang LL, Liu JQ, Bai XZ, Fan L, Han F, Jia WB, et al. Acute downregulation of miR-155 at wound sites leads to a reduced fibrosis through attenuating inflammatory response. Biochem Biophys Res Commun. 2014; 453(1): 153-159. doi: 10.1016/j.bbrc.2014.09.077 PMID: 25264197
51. Connolly MK, Bedrosian AS, Mallen-St Clair J, Mitchell AP, Ibrahim J, Stroud A, et al. In liver fibrosis, dendritic cell govern hepatic inflammation in mice via TNFα. J Clin Invest. 2009; 119: 3213-3225. doi: 10.1172/JCI37581 PMID: 19855130
52. Pradere JP, Kluwe J, De Minicis S, Jiao JJ, Gwak GY, Dapito DH, et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology 2013; 1461-1473.
53. Bataller R, Schwabe RF, Choi WY, Paik YH, Lindquist J, Qian T, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest. 2003; 112: 1383-1394. PMID: 14597764
54. Cicchini C, Amicone L, Alonzi T, Marchetti A, Macone C, Tripodi M. Molecular mechanisms controlling the phenotype and the EMT/MET dynamics of hepatocyte. Liv Int. 2014; In Press, 2015 Feb;35(2):302-10. doi: 10.1111/liv.12577
55. Taura K, Miura K, Iwaisako K, Osterreicher CH, Kodama Y, Penz-Osterreicher M, et al. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology 2010; 51: 1027-1036. doi: 10.1002/hep.23368 PMID: 20052656
56. Bala S, Csak T, Petrasek J, Catalano D, Kodys K, Szabo G. MiRNA-155 regulates CCl4-induced liver inflammation and fibrosis via targeting pro- inflammatory and pro-fibrotic genes. Hepatology 2012; 56 (4) Suppl: .:1107A (#1968) doi: 10.1016/j.jvs.2012.04.010 PMID: 22818832
57. Csak T, Bala S, Lippai D, Satishchandran A, Catalano D, Kodys K, et al. microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int. 2015; 35(2): 532-541. doi: 10.1111/liv.12633 PMID: 25040043